dc.contributor.author | Brekke, Kurt R. | |
dc.contributor.author | Dalen, Dag Morten | |
dc.contributor.author | Strøm, Steinar | |
dc.date.accessioned | 2013-05-03T11:31:59Z | |
dc.date.available | 2013-05-03T11:31:59Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 1904-4526 (trykt utgave) | |
dc.identifier.uri | http://hdl.handle.net/11250/93886 | |
dc.description | This is an Open Access journal. www.norden.org | no_NO |
dc.description.abstract | Pharmaceuticals account for almost a fifth of total health spending in
OECD-countries. Both pharmaceutical innovations and the aging of the
population explain the increasing importance of pharmaceuticals in health
care. Due to the importance of patent protection and insurance coverage,
pharmaceutical markets are subjected to economic regulation – both on
the supply-side and the demand-side. In this paper, we briefly review the
Nordic pharmaceutical market, before explaining the main regulatory
policy measures taken by governments in these countries. Empirical research
has been undertaken to investigate regulation and competition, and
we provide a review of some of the findings. | no_NO |
dc.language.iso | eng | no_NO |
dc.publisher | Nordisk ministerråd | no_NO |
dc.subject | pharmaceutical markets | no_NO |
dc.subject | pharmaceutical costs | no_NO |
dc.subject | reference pricing | no_NO |
dc.subject | price cap | no_NO |
dc.subject | health insurance | no_NO |
dc.title | Should pharmaceutical costs be curbed? | no_NO |
dc.type | Journal article | no_NO |
dc.type | Peer reviewed | no_NO |
dc.source.pagenumber | 247-277 | no_NO |
dc.source.journal | Nordic Economic Policy Review | no_NO |
dc.source.issue | 2 | no_NO |
dc.identifier.doi | http://dx.doi.org/10.6027/TN2013-514 | |